EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A circRNA neoantigen vaccine elicits potent antitumor immunity and synergizes with checkpoint blockade in melanoma

Pan Wu, Junshang Ge, Xiangchan Hou, Hongke Qu, Jiawei Ouyang, Dan Wang, Tong Tong, Yi Meng, Qijia Yan, Lei Shi, Zhaojian Gong, Pan Chen und 6 weitere

Cancer Letters · 2026-06 · 648 · 218459

DOI: 10.1016/j.canlet.2026.218459 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026-06. Verfasst von Pan Wu und 17 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiang…. Hauptthemen laut MEDLINE: Cancer Vaccines, Antigens, Neoplasm, Immune Checkpoint Inhibitors, RNA, Circular. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Hunan Provincial Natural Science Foundation, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer immunotherapy harnesses and amplifies the host's anti-tumor immune responses to eradicate malignant cells. Tumor neoantigens serve as ideal targets due to high specificity and immunogenicity. Circular RNA (circRNA), with a stable covalently closed structure, can be engineered as a novel vector for neoantigen expression. Here, we developed a circRNA-based vaccine encoding multiple melanoma neoantigens (circRNAMNA). circRNAMNA significantly suppressed tumor growth in both prophylactic and therapeutic murine models and induced robust anti-tumor immunity. Mechanistically, using single-cell RNA sequencing, we elucidated the antitumor mechanisms and alterations in the tumor and immune microenvironment following vaccination. circRNAMNA immunization nearly eliminated the Ccl6+Mel subcluster-highly active in chemokine signaling, leukocyte recruitment, and antigen presentation pathways. While residual Cdk1+Mel and Cdhr4+Mel subclusters exhibited downregulation of immune-response-related pathways. Furthermore, circRNAMNA vaccination reshaped myeloid cell composition, markedly increasing infiltration of monocytes/macrophages (Monocyte/MФ) with antitumor phenotypes, including classical inflammatory monocytes (Mono-Vcan), Macro-C1qc, and activated M1-like macrophages (Macro-Ifng). Chemokine signaling was enriched in Ccl6+Mel and Monocyte/MФ clusters. Moreover, circRNAMNA enhanced T cell-mediated antitumor responses, elevating T cell receptor (TCR) clonotype diversity and expansion of TCR clonotypes especially in CD4+ effector (CD4 Eff) and CD8+ cytotoxic (CD8 Cyto) T cells. Notably, Tigit was identified as the most highly expressed checkpoint receptor in CD8+ exhausted T cells (CD8 Tex), and combining circRNAMNA with anti-TIGIT/PD1 blockade produced synergistic antitumor effects. Collectively, this study systematically elucidates the therapeutic potential and immune mechanisms of the neoantigen circRNA vaccine in melanoma, providing a mechanistic framework for developing personalized RNA vaccines and rational combination immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesAntigens, NeoplasmImmune Checkpoint InhibitorsRNA, CircularMelanomaMelanoma, ExperimentalAnimalsMiceHumansCell Line, TumorTumor MicroenvironmentFemaleMice, Inbred C57BL

Stichwörter der Autor:innen

Combination therapyTumor neoantigencircRNA vaccinescRNA-seq

Substanzen

Cancer VaccinesAntigens, NeoplasmImmune Checkpoint InhibitorsRNA, Circular

Autor:innen und Institutionen

  • NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, Chin…
  • Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute and Xiangya School of Basic Medical Sciences, Central South University, Changsha, Hunan, China.
  • Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute and Xiangya School of Basic Medical Sciences, Central South University, Changsha, Hunan, China; Depart…
  • Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute and Xiangya School of Basic Medical Sciences, Central South University, Changsha, Hunan, China; FuRong…

Förderung

  • National Natural Science Foundation of China
  • Hunan Provincial Natural Science Foundation
  • China Postdoctoral Science Foundation
  • Science and Technology Program of Hunan Province
  • Hunan Provincial Science and Technology Department

Zitieren

APA

Wu, P., Ge, J., Hou, X., Qu, H., Ouyang, J., Wang, D., Tong, T., Meng, Y., Yan, Q., Shi, L., Gong, Z., Chen, P., Xiang, B., Zhou, M., Tan, M., Zhang, W., Zeng, Z., & Xiong, W. (2026). A circRNA neoantigen vaccine elicits potent antitumor immunity and synergizes with checkpoint blockade in melanoma. Cancer Letters, 648, 218459. https://doi.org/10.1016/j.canlet.2026.218459

Vancouver

Wu P, Ge J, Hou X, Qu H, Ouyang J, Wang D, et al. A circRNA neoantigen vaccine elicits potent antitumor immunity and synergizes with checkpoint blockade in melanoma. Cancer Letters. 2026;648:218459. doi:10.1016/j.canlet.2026.218459

BibTeX
@article{Wu2026,
  author = {Wu, Pan and Ge, Junshang and Hou, Xiangchan and Qu, Hongke and Ouyang, Jiawei and Wang, Dan and Tong, Tong and Meng, Yi and Yan, Qijia and Shi, Lei and Gong, Zhaojian and Chen, Pan and Xiang, Bo and Zhou, Ming and Tan, Ming and Zhang, Wenling and Zeng, Zhaoyang and Xiong, Wei},
  title = {A circRNA neoantigen vaccine elicits potent antitumor immunity and synergizes with checkpoint blockade in melanoma},
  journal = {Cancer Letters},
  year = {2026},
  volume = {648},
  pages = {218459},
  doi = {10.1016/j.canlet.2026.218459}
}
Kostenlos starten →